Cellular immunotherapy is unfamiliar and familiar to ordinary people. Unfamiliar with not understanding its treatment mechanism, familiar with the Wei Zexi incident reported in previous news.

In fact, in simple terms, there are many cells in the immune system. The DC-CIK biological immunotherapy used by Wei Zexi is only dendritic cells (DC cells) and cytokine-induced killer cells (CIK cells) in immune cells. Not good can not negate the potential of other cellular immunotherapy because there are many targets for functioning in the immune system.

Moreover, PD-1 and Car-T, which are hot to hot, have been told by the clinical trials once and for all, please don't worry about it, and immunotherapy is very reliable.

Types of Solid Tumor Cancers (Source genengnews.com)

Car-T (Chinese name is chimeric antigen receptor T cell technology), popularly speaking, allows T cells to express proteins that bind to tumor cell surface proteins, thereby stimulating cellular immunity and accurately identifying and killing tumor cells. Although it is only the tip of the iceberg of cellular immunotherapy, Car-T has become famous. In 2012, Carl H. June, an inventor of the American Academy of Sciences and a tenured professor of the University of Pennsylvania, applied Car-T therapy to leukemia girl Emily Whitehead, and the spokesperson has been Has been alive for 5 years.

At present, the major companies in the CAR-T field are Novartis, Cellectis, Juno, Kite Pharma, etc. Some of these patents have also been patented in China, but this is known as a new treatment technology for cancer, a patent in China. Authorized on the road, but all the way.

Mr. Yang’s sister will briefly describe a few core patents today.

Prof. June, a partner of Novartis, has been involved in the invention of 61 PCT international patents. As an applicant, he has applied for 31 PCT patents covering CD19 targets, T cells, tumor cells, cell banks, transgenic animal models, etc. Multi-domain (see Figure 1, where blue represents Professor PCT as the applicant's PCT patent).

Among them, 14 PCT patents entered China, except for 4 patents that have expired, and other patents are in the state of trial. At present, as a big cow in the field of cellular immunity, it is necessary to say that Professor June's emphasis on patents is worthy of being imitated by many researchers, but the road to patent distribution in China has been extremely difficult.

figure 1. Prof. June's PCT Patent Cluster Diagram

Liquid Injection

Tetanus Shot,Tetanus Vaccine,Hepatitis B Injection,Hep B Vaccine

FOSHAN PHARMA CO., LTD. , https://www.foshanmedicine.com